Symbols / XBIO $3.38 +19.60%
XBIO Chart
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop DNase technology for the treatment of immunotherapies. The company offers under XDNASE, XCART, OncoHist, PolyXen, ErepoXen, and ImuXen trandemarks. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.74M |
| Enterprise Value | 2.31M | Income | -3.16M | Sales | 2.86M |
| Book/sh | 2.56 | Cash/sh | 1.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -5.12 | PEG | — |
| P/S | 2.71 | P/B | 1.32 | P/C | — |
| EV/EBITDA | — | EV/Sales | 0.81 | Quick Ratio | 3.71 |
| Current Ratio | 4.56 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.58 | EPS next Y | -0.66 | EPS Growth | — |
| Revenue Growth | 67.20% | Earnings | 2026-03-12 17:00 | ROA | -31.56% |
| ROE | -57.43% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -53.04% | Profit Margin | -110.40% | Shs Outstand | 2.29M |
| Shs Float | 1.88M | Short Float | 2.28% | Short Ratio | 2.21 |
| Short Interest | — | 52W High | 13.93 | 52W Low | 1.90 |
| Beta | 2.32 | Avg Volume | 25.32K | Volume | 115.96K |
| Target Price | — | Recom | None | Prev Close | $2.83 |
| Price | $3.38 | Change | 19.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.38
Latest analyst target
3. DCF / Fair value
$-20.81
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.38
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-09 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-20 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-05-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
- Xenetic Biosciences: Q4 Earnings Snapshot - 10TV hu, 12 Mar 2026 22
- Xenetic Advances Novel DNase-CAR T Cancer Therapy Program with Scripps, Reports $4.8M Cash Position - Stock Titan Wed, 13 Aug 2025 07
- Is Xenetic Biosciences Stock Built to Withstand More Downside? - Trefis Fri, 19 Dec 2025 08
- Xenetic (XBIO) Reports Increased Revenue and Advances Clinical D - GuruFocus Fri, 13 Mar 2026 17
- Why Are Pharmaceutical Stocks XBIO, UPC, XTLB, & ACXP Up Today? - TipRanks Wed, 08 Oct 2025 07
- XBIO Shares Skyrocket: Exploring the Surge - StocksToTrade Wed, 08 Oct 2025 07
- Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - TechStock² Wed, 08 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 14 Feb 2024 13
- Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges - Benzinga Fri, 10 Oct 2025 07
- XBIO Stock Alert: Riding the Market Waves - timothysykes.com Wed, 08 Oct 2025 07
- Xenetic Biosciences Prices $4.5 Million Stock Offering; Shares Fall - marketscreener.com Fri, 10 Oct 2025 07
- Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Wed, 08 Oct 2025 14
- Xenetic Biosciences prices $4.5 million common stock offering By Investing.com - Investing.com South Africa Fri, 10 Oct 2025 07
- Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - marketscreener.com Wed, 09 Apr 2025 07
- Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - Stock Titan Mon, 16 Dec 2024 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -2.83M | -4.20M | -4.52M | -6.69M |
| TotalUnusualItems | 0.00 | |||
| TotalUnusualItemsExcludingGoodwill | 0.00 | |||
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.68M | -3.96M | -4.13M | -6.55M |
| ReconciledDepreciation | 0.00 | 27.04K | 35.48K | |
| EBITDA | -2.83M | -4.20M | -4.52M | -6.69M |
| EBIT | -2.83M | -4.20M | -4.52M | -6.72M |
| NetInterestIncome | 148.00K | 249.86K | 355.76K | 167.15K |
| InterestIncome | 148.00K | 249.86K | 355.76K | 167.15K |
| NormalizedIncome | -2.68M | -3.96M | -4.13M | -6.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.68M | -3.96M | -4.13M | -6.55M |
| TotalExpenses | 5.81M | 6.70M | 7.06M | 8.42M |
| TotalOperatingIncomeAsReported | -2.83M | -4.20M | -4.52M | -6.72M |
| DilutedAverageShares | 1.70M | 1.54M | 1.53M | 1.42M |
| BasicAverageShares | 1.70M | 1.54M | 1.53M | 1.42M |
| DilutedEPS | -1.58 | -2.57 | -2.71 | -4.61 |
| BasicEPS | -1.58 | -2.57 | -2.71 | -4.61 |
| DilutedNIAvailtoComStockholders | -2.68M | -3.96M | -4.13M | -6.55M |
| NetIncomeCommonStockholders | -2.68M | -3.96M | -4.13M | -6.55M |
| NetIncome | -2.68M | -3.96M | -4.13M | -6.55M |
| NetIncomeIncludingNoncontrollingInterests | -2.68M | -3.96M | -4.13M | -6.55M |
| NetIncomeContinuousOperations | -2.68M | -3.96M | -4.13M | -6.55M |
| TaxProvision | 0.00 | |||
| PretaxIncome | -2.68M | -3.96M | -4.13M | -6.55M |
| OtherIncomeExpense | 5.72K | -5.71K | 25.38K | -1.60K |
| OtherNonOperatingIncomeExpenses | 5.72K | -5.71K | 25.38K | -1.60K |
| SpecialIncomeCharges | 0.00 | |||
| ImpairmentOfCapitalAssets | 0.00 | |||
| NetNonOperatingInterestIncomeExpense | 148.00K | 249.86K | 355.76K | 167.15K |
| InterestIncomeNonOperating | 148.00K | 249.86K | 355.76K | 167.15K |
| OperatingIncome | -2.83M | -4.20M | -4.52M | -6.72M |
| OperatingExpense | 5.81M | 6.70M | 7.06M | 8.42M |
| ResearchAndDevelopment | 3.07M | 3.29M | 3.49M | 4.77M |
| SellingGeneralAndAdministration | 2.75M | 3.42M | 3.56M | 3.65M |
| GeneralAndAdministrativeExpense | 2.75M | 3.42M | 3.56M | 3.65M |
| OtherGandA | 2.75M | 3.42M | 3.56M | 3.65M |
| TotalRevenue | 2.98M | 2.50M | 2.54M | 1.71M |
| OperatingRevenue | 2.98M | 2.50M | 2.54M | 1.71M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 2.70K | 2.70K | 2.70K | 2.70K |
| OrdinarySharesNumber | 2.29M | 1.54M | 1.54M | 1.52M |
| ShareIssued | 2.29M | 1.54M | 1.54M | 1.52M |
| TangibleBookValue | 7.39M | 6.01M | 9.79M | 13.64M |
| InvestedCapital | 7.39M | 6.01M | 9.79M | 13.64M |
| WorkingCapital | 7.08M | 5.69M | 8.78M | 12.58M |
| NetTangibleAssets | 7.40M | 6.01M | 9.80M | 13.65M |
| CommonStockEquity | 7.39M | 6.01M | 9.79M | 13.64M |
| PreferredStockEquity | 1.45K | 1.80K | 1.80K | 2.77K |
| TotalCapitalization | 7.40M | 6.01M | 9.80M | 13.65M |
| TotalEquityGrossMinorityInterest | 7.40M | 6.01M | 9.80M | 13.65M |
| StockholdersEquity | 7.40M | 6.01M | 9.80M | 13.65M |
| GainsLossesNotAffectingRetainedEarnings | 253.73K | 253.73K | 253.73K | 253.73K |
| OtherEquityAdjustments | 253.73K | 253.73K | 253.73K | 253.73K |
| TreasuryStock | 5.28M | 5.28M | 5.28M | 5.28M |
| RetainedEarnings | -199.88M | -197.19M | -193.23M | -189.10M |
| AdditionalPaidInCapital | 212.29M | 208.23M | 208.05M | 207.77M |
| CapitalStock | 3.75K | 3.35K | 3.35K | 4.29K |
| CommonStock | 2.29K | 1.54K | 1.54K | 1.52K |
| PreferredStock | 1.45K | 1.80K | 1.80K | 2.77K |
| TotalLiabilitiesNetMinorityInterest | 968.02K | 894.26K | 809.59K | 1.07M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 968.02K | 894.26K | 809.59K | 1.07M |
| OtherCurrentLiabilities | 23.88K | 34.20K | 48.26K | 39.95K |
| PayablesAndAccruedExpenses | 944.15K | 860.06K | 761.33K | 1.03M |
| CurrentAccruedExpenses | 686.04K | 576.45K | 520.50K | 745.85K |
| Payables | 258.11K | 283.62K | 240.83K | 287.36K |
| AccountsPayable | 258.11K | 283.62K | 240.83K | 287.36K |
| TotalAssets | 8.36M | 6.90M | 10.61M | 14.72M |
| TotalNonCurrentAssets | 313.92K | 313.92K | 1.02M | 1.07M |
| OtherNonCurrentAssets | 313.92K | 313.92K | 1.02M | 1.07M |
| NetPPE | 0.00 | |||
| AccumulatedDepreciation | -50.24K | |||
| GrossPPE | 50.24K | |||
| MachineryFurnitureEquipment | 50.24K | |||
| CurrentAssets | 8.05M | 6.59M | 9.59M | 13.65M |
| OtherCurrentAssets | 166.29K | 421.95K | 603.83K | 556.09K |
| PrepaidAssets | 556.09K | 479.40K | ||
| CashCashEquivalentsAndShortTermInvestments | 7.88M | 6.17M | 8.98M | 13.10M |
| CashAndCashEquivalents | 7.88M | 6.17M | 8.98M | 13.10M |
| CashFinancial | 7.88M | 6.17M | 8.98M | 13.10M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.29M | -2.82M | -4.11M | -5.15M |
| IssuanceOfCapitalStock | 4.00M | 1.00 | 0.00 | 11.45M |
| CapitalExpenditure | -500.00K | |||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 7.88M | 6.17M | 8.98M | 13.10M |
| BeginningCashPosition | 6.17M | 8.98M | 13.10M | 18.24M |
| ChangesInCash | 1.72M | -2.82M | -4.11M | -5.15M |
| FinancingCashFlow | 4.00M | 0.00 | 0.00 | 11.45M |
| CashFlowFromContinuingFinancingActivities | 4.00M | 1.00 | 0.00 | 11.45M |
| NetOtherFinancingCharges | -1.00 | |||
| ProceedsFromStockOptionExercised | 0.00 | 3.68K | ||
| NetCommonStockIssuance | 4.00M | 1.00 | 0.00 | 11.45M |
| CommonStockIssuance | 4.00M | 1.00 | 0.00 | 11.45M |
| InvestingCashFlow | 0.00 | -500.00K | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 0.00 | -500.00K | 0.00 | |
| NetIntangiblesPurchaseAndSale | 0.00 | -500.00K | 0.00 | |
| PurchaseOfIntangibles | 0.00 | -500.00K | 0.00 | |
| OperatingCashFlow | -2.29M | -2.82M | -4.11M | -4.65M |
| CashFlowFromContinuingOperatingActivities | -2.29M | -2.82M | -4.11M | -4.65M |
| ChangeInWorkingCapital | 329.42K | 970.98K | -262.73K | -426.69K |
| ChangeInOtherCurrentAssets | 0.00 | 704.43K | 48.58K | 25.00K |
| ChangeInPayablesAndAccruedExpense | 73.76K | 84.68K | -263.57K | -347.95K |
| ChangeInPayable | 73.76K | 84.68K | -263.57K | -347.95K |
| ChangeInAccountPayable | 73.76K | 84.68K | -263.57K | -347.95K |
| ChangeInPrepaidAssets | 255.66K | 181.87K | -47.73K | -103.74K |
| OtherNonCashItems | 1.79M | |||
| StockBasedCompensation | 64.79K | 171.81K | 283.08K | 511.48K |
| AssetImpairmentCharge | 0.00 | |||
| DeferredTax | 0.00 | |||
| DeferredIncomeTax | 0.00 | |||
| DepreciationAmortizationDepletion | 0.00 | 27.04K | 35.48K | |
| DepreciationAndAmortization | 0.00 | 27.04K | 35.48K | |
| Depreciation | 0.00 | 27.04K | 35.48K | |
| NetIncomeFromContinuingOperations | -2.68M | -3.96M | -4.13M | -6.55M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XBIO
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|